Literature DB >> 6280173

Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA.

J P Weir, G Bajszár, B Moss.   

Abstract

A selective plaque assay that uses thymidine kinase (TK)-deficient human 143 cells was developed to titer mixtures of TK(+) and TK(-) vaccinia virus. With this assay it could be shown that methotrexate-resistant TK(+) virus was formed in cells coinfected with TK(-) virus and wild-type virus DNA. By substituting vaccinia DNA fragments cloned in plasmids for virion DNA, this marker rescue system provided the basis for mapping the TK gene. Of the 15 HindIII fragments, only J could rescue five independently derived TK(-) mutants. This 5000-base-pair (bp) fragment maps approximately 80,000 bp from the left-end of the 180,000-bp vaccinia genome. Marker rescue could be detected with 18 ng or less of plasmid and was proportionate to DNA concentration. The resistance to methotrexate of the TK(+) recombinants was shown to be due to TK synthesis. Evidence that the HindIII J fragment contains the structural TK gene and not a regulatory element was demonstrated by the synthesis of active TK in a cell-free system programmed with mRNA selected by hybridization to the plasmid. Previous studies [Belle-Isle, H., Venkatesan, S. & Moss, B. (1981) Virology 112, 306-317] indicated that mRNAs coding for three immediate early polypeptides with molecular weights of 41,000, 21,000, and 17,000 map within HindIII J. The mapping of the easily selectable vaccinia virus TK gene now opens the way to genetic manipulations that should increase our understanding of vaccinia virus gene expression and facilitate the use of vaccinia virus as an efficient cloning vector for foreign genes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6280173      PMCID: PMC345931          DOI: 10.1073/pnas.79.4.1210

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Non-producer human cells induced by murine sarcoma virus.

Authors:  J S Rhim; H Y Cho; R J Huebner
Journal:  Int J Cancer       Date:  1975-01-15       Impact factor: 7.396

2.  Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells.

Authors:  M Wigler; S Silverstein; L S Lee; A Pellicer; Y c Cheng; R Axel
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

3.  Purification of vaccinia virus-induced thymidine kinase activity from [35S]methionine-labeled cells.

Authors:  S Kit; G N Jorgensen; A Liav; V Zaslavsky
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

4.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

5.  Characterization and mixed infections of three strains of vaccinia virus: wild type, IBT-resistant and IBT-dependent mutants.

Authors:  E Katz; E Margalith; B Winer; A Lazar
Journal:  J Gen Virol       Date:  1973-12       Impact factor: 3.891

6.  Rifampicin inhibits the growth of some mammalian viruses.

Authors:  J H Subak-Sharpe; M C Timbury; J F Williams
Journal:  Nature       Date:  1969-04-26       Impact factor: 49.962

7.  Poxvirus DNA-dependent RNA polymerase.

Authors:  J R Kates; B R McAuslan
Journal:  Proc Natl Acad Sci U S A       Date:  1967-07       Impact factor: 11.205

8.  RNA polymerase activity in purified infectious vaccinia virus.

Authors:  W Munyon; E Paoletti; J T Grace
Journal:  Proc Natl Acad Sci U S A       Date:  1967-12       Impact factor: 11.205

9.  An efficient mRNA-dependent translation system from reticulocyte lysates.

Authors:  H R Pelham; R J Jackson
Journal:  Eur J Biochem       Date:  1976-08-01

10.  Biochemical transformation of mouse cells by fragments of herpes simplex virus DNA.

Authors:  N J Maitland; J K McDougall
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

View more
  78 in total

1.  Clustered charge-to-alanine mutagenesis of the vaccinia virus H5 gene: isolation of a dominant, temperature-sensitive mutant with a profound defect in morphogenesis.

Authors:  J DeMasi; P Traktman
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Role of vaccinia virus A20R protein in DNA replication: construction and characterization of temperature-sensitive mutants.

Authors:  K Ishii; B Moss
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Transcriptional mapping and nucleotide sequence of a vaccinia virus gene encoding a polypeptide with extensive homology to DNA ligases.

Authors:  G L Smith; Y S Chan; S M Kerr
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

4.  Vaccinia virus encodes a thymidylate kinase gene: sequence and transcriptional mapping.

Authors:  G L Smith; A de Carlos; Y S Chan
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

5.  Vaccinia virus induces ribonucleotide reductase in primate cells.

Authors:  M B Slabaugh; T L Johnson; C K Mathews
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

6.  Vaccinia virus-induced ribonucleotide reductase can be distinguished from host cell activity.

Authors:  M B Slabaugh; C K Mathews
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

7.  Chromosome mapping of Rmp-4, a gonad-dependent gene encoding host resistance to mousepox.

Authors:  D G Brownstein; L Gras
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 8.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

9.  Effect of marker distance and orientation on recombinant formation in poxvirus-infected cells.

Authors:  R J Parks; D H Evans
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.